This policy identifies which noninvasive tests for hepatic fibrosis Aetna considers medically necessary, which are experimental/investigational (not covered), and important constraints and limitations that affect appropriate use and claims documentation. The policy lists covered modalities including transient elastography (e.g., FibroScan), FibroTest‑ActiTest/HCV‑FibroSure, magnetic resonance elastography (MRE) for certain NASH indications, and the Enhanced Liver Fibrosis (ELF) test, and it also specifies multiple procedures and biomarkers considered investigational (for example, ARFI, quantitative mpMRI/LiverMultiScan, serum ferritin, and various miRNA assays).

When tests are used clinically, claims should match the listed CPT/HCPCS and ICD‑10 coding and be supported by documentation of the clinical indication and numeric test results where applicable (for example, FibroTest score, ELF index, or median liver stiffness in kPa). The policy identifies numerous CPT and ICD‑10 codes that are not covered for investigational indications (for example, quantitative MRI CPT codes 0648T–0724T and ferritin CPT code 82728) and notes that artificial intelligence approaches currently have no specific billing code and are considered investigational for fibrosis/NAFLD applications.

The coverage stance emphasizes that noninvasive tests have the greatest validated utility for identifying advanced fibrosis or cirrhosis rather than for distinguishing early or intermediate stages. Guideline and systematic‑review evidence cited in the policy indicate that serum marker panels and imaging techniques can reduce the need for biopsy in some patients but none fully supplants liver biopsy across all clinical scenarios. UpToDate and guideline summaries are cited to support that serum assays and imaging remain imperfect substitutes for histology.

The policy includes explicit constraints to limit overuse and duplicate testing: performance of transient elastography, FibroTest‑ActiTest/HCV‑FibroSure, MRE, or ELF more than twice per year is considered not medically necessary, and repeating any of these noninvasive fibrosis tests within 6 months following a liver biopsy or another listed fibrosis test is considered not medically necessary and may be denied. It also notes contexts in which specific tests are unreliable or not indicated (for example, transient elastography is unreliable during episodes of acute liver injury and noninvasive tests have no role in diagnosing glycogenic hepatopathy in place of biopsy).

The document highlights evidence limitations for emerging technologies: mpMRI/LiverMultiScan and other quantitative MRI indices have limited multicenter and cross‑vendor validation and therefore are considered investigational pending broader validation; published single‑center studies require further prospective, multi‑site validation before routine clinical replacement of biopsy. Similarly, the policy cites studies showing lack of correlation (e.g., serum ACE with fibrosis stage) or inadequate sensitivity/specificity (e.g., CK‑18 for NASH) to justify investigational determinations for several serum markers.

Finally, the policy underscores provider documentation expectations and authorization considerations: when reporting elastography include the median kPa and number of valid measurements, document numeric serum panel scores when used for management, and submit claims with the matching diagnosis codes. The policy does not specify a uniform prior authorization requirement in the excerpt; providers are directed to the Clinical Policy Bulletin and plan provisions for any plan‑specific prior authorization rules.

The policy excerpt contains no single blanket exclusion list phrased as universal coverage denials in these chunks, but it does enumerate numerous investigational indications and associated CPT/ICD‑10 entries for which coverage is not supported. International and guideline sources cited in the background sections (for example, AASLD/WHO/NIH reviews and systematic reviews) do not endorse routine replacement of biopsy by noninvasive tests because of variable accuracy and incomplete validation.

Guideline context and systematic reviews summarized in the policy consistently note that noninvasive approaches may be useful as screening or to exclude advanced fibrosis, and that combining serum indices with elastography can improve diagnostic accuracy and reduce the need for biopsy in some patient groups. However, these sources also advise caution: many noninvasive tests have indeterminate zones, and external validation of stage‑specific cutoffs is often lacking, which limits universal adoption and supports selective, indication‑driven use rather than broad replacement of histologic assessment.

The policy reinforces the evidence‑based conclusion that no serum test can fully supplant liver biopsy. UpToDate and systematic review citations emphasize that while serum marker panels and algorithms (e.g., FibroTest/FibroSure, HepaScore, APRI/FIB‑4) provide useful, noninvasive risk stratification, they have limitations including variable specificity for liver‑derived fibrosis, susceptibility to confounding by inflammation or comorbid conditions, and discordance with biopsy in a substantial minority of cases. Consequently, biopsy remains the reference standard when definitive staging or diagnostic clarity is required.

The policy explicitly warns that transient elastography (FibroScan) should not be relied upon to diagnose pre‑existing cirrhosis during episodes of acute liver injury. Cited evidence (Sagir et al.) demonstrates that liver stiffness measurements are frequently and transiently elevated in acute hepatic injury, producing false‑positive values suggestive of cirrhosis that resolve as the acute process abates. Testing performed in this setting may therefore be misleading and can result in inappropriate clinical conclusions or interventions.

Consistent with the above, the policy describes that transient elastography (TE) is unsuitable for detecting cirrhosis/fibrosis in patients with acute liver damage because TE frequently yields pathologically high values during acute hepatitic episodes. The background literature and technology assessments note that inflammation and elevated bilirubin can confound stiffness measurements, and recommend against relying on TE results obtained during the acute phase for chronic fibrosis staging.

For glycogenic hepatopathy (GH), the policy states that noninvasive tests such as FibroScan or FibroTest have no role in diagnosing GH or in distinguishing GH from NAFLD; liver biopsy remains the diagnostic gold standard when the diagnosis is uncertain. Reviews and case series cited indicate that GH is clinically and biochemically similar to NAFLD and that imaging and serum tests are not pathognomonic, so biopsy or other definitive approaches may be required for diagnostic certainty in select patients.

The evidence for multiparametric MRI approaches (for example, LiverMultiScan, cT1‑based indices) is described as promising but limited. The policy notes that single‑center studies and small cohorts report correlations between mpMRI parameters and histologic measures and that combined mpMRI indices have shown favorable diagnostic AUCs for NASH in early studies, but cross‑vendor, multi‑center validation is lacking. Consequently, mpMRI / LiverMultiScan is considered investigational pending further validation and prospective outcome data.

Guideline context in the policy indicates that UpToDate and other reviews do not presently include mpMRI/LiverMultiScan as an established management tool for NAFLD/NASH. While mpMRI techniques are noted as technically promising for quantifying fat, iron, and fibroinflammatory change, major reviews and guideline summaries cited in the policy do not endorse mpMRI as a routine replacement for biopsy or standard management pathways, pending more extensive validation.

The policy cites evidence that serum angiotensin‑converting enzyme (ACE) levels do not correlate with histologic fibrosis stage in chronic hepatitis C. Akar and colleagues found no statistical relationship between serum ACE and fibrosis stage in CHC cohorts, indicating that ACE is not supported as a diagnostic marker for staging hepatic fibrosis in the cited study population.

Authors of studies and reviews summarized in the policy note that elastography cannot currently replace liver biopsy to distinguish acute cellular rejection from recurrent disease or other graft pathology after transplantation. Evidence to date is limited, cutoffs are inconsistent, and confounding vascular or biliary changes may alter elastography results. Although TE may be useful as a noninvasive adjunct in transplant follow‑up research, the policy indicates that biopsy remains required when distinguishing rejection from other graft disorders.

The reference excerpts included in the policy do not present an enumerated list of universal coverage exclusions beyond the investigational indications and code listings already described; rather, they summarize the literature and guideline positions that inform the policy. Investigational determinations are supported by cited evidence gaps and validation limitations rather than by a single explicit exclusion clause in the background citations.

The policy reiterates that transient elastography is unreliable for detecting cirrhosis in the setting of acute liver damage; the Sagir et al. study showed that many patients with acute liver injury had transiently elevated liver stiffness suggestive of cirrhosis despite no clinical, imaging, or histologic evidence of cirrhosis. Therefore TE results obtained during acute hepatic injury should not be used to infer chronic cirrhosis without further corroboration.

To limit unnecessary utilization the policy defines an overfrequency constraint: performance of listed noninvasive fibrosis tests (transient elastography, FibroTest‑ActiTest/HCV‑FibroSure, magnetic resonance elastography, and ELF) in excess of 2 times per year is considered not medically necessary. Additionally, repeating these tests within 6 months after a liver biopsy or another specified fibrosis test is considered not medically necessary. These thresholds are intended to balance clinical monitoring needs with the limited evidence supporting frequent serial testing and to reduce duplicative testing.

The policy reflects the evidence‑based conclusion that serum marker models and other noninvasive tests are currently insufficiently accurate to routinely replace liver biopsy for staging hepatic fibrosis in many patients. Systematic reviews and guideline statements cited indicate that while noninvasive tests are helpful for excluding advanced fibrosis or identifying patients who may not require immediate biopsy, their variable accuracy across etiologies, indeterminate ranges, and confounding factors limit universal replacement of histologic assessment.

Beyond the specific overfrequency and timing limitations, the policy does not list additional discrete scenarios labeled as 'not medically necessary' in these excerpts; rather, it emphasizes investigational status or limited evidence for specific technologies and clinical contexts. The investigational list includes multiple serum tests, imaging modalities (quantitative mpMRI), and procedural indications for TE (eg, routine transplant surveillance, glycogenic hepatopathy diagnosis, esophageal varices detection) where evidence is insufficient to support routine coverage.

The policy underscores that noninvasive tests should not be used to universally replace liver biopsy for all patients. Guideline and meta‑analytic evidence in the excerpts indicate that these tests are most reliable for detecting advanced fibrosis or cirrhosis and perform less well for early or intermediate fibrosis stages. Where definitive staging impacts management, or where noninvasive results are discordant or indeterminate, liver biopsy remains indicated.

Sequential or combined strategies (for example, initial serum screening with FIB‑4/APRI followed by ELF or TE for indeterminate results) are discussed in the background as approaches that can increase diagnostic accuracy and may reduce but not eliminate the need for biopsy; such strategies require clinical judgment and, in some cases, further validation.

The policy cautions that elastography techniques currently lack validated, universally accepted stiffness cutoffs for definitive noninvasive staging across all fibrosis stages. Meta‑analyses and reviews note a wide range and overlap of stiffness thresholds between stages and emphasize that no optimal stiffness cut‑offs for individual fibrosis stages have been validated in independent cohorts. Thus, TE and related elastography results should be interpreted within the clinical context and, in many cases, used in combination with serum markers or imaging rather than as standalone definitive stage assignments.

The background and coding excerpts do not present a concise single‑sentence 'not medically necessary' statement beyond the overfrequency and duplicate testing rules; rather, the investigational determinations, limitations, and absence of sufficient evidence for particular tests and indications serve as the rationale for noncoverage of those listed procedures and codes. The policy therefore relies on evidence summaries and investigational listings to delineate noncoverage rather than on an additional blanket NMN statement within the provided excerpts.

The policy states that mpMRI/LiverMultiScan and other quantitative multiparametric MRI techniques are not established to broadly replace liver biopsy. Early validation studies show correlation with histology for parameters such as cT1 and PDFF and reasonable diagnostic performance in select cohorts, but limitations include small, single‑center study populations, lack of independent validation cohorts, and potential cross‑vendor variability; therefore, mpMRI is currently classified investigational for general fibrosis staging pending further evidence.

Evidence is insufficient to support imaging alone to diagnose NASH or to rely on single serum biomarkers for NASH staging. Systematic reviews and pooled analyses report that imaging modalities (including MRE) and biomarkers such as CK‑18 have limited sensitivity or heterogeneous performance for NASH; CK‑18 in particular shows modest AUROC values and limited sensitivity, making it inadequate as a lone screening or staging test. The policy therefore treats these modalities as adjunctive and requiring further validation before routine standalone diagnostic use.

The policy repeatedly documents limitations in the evidence base and the need for further research and multicenter validation for several emerging techniques (including mpMRI indices, AI/ML models, and some serum biomarkers). Single‑center studies, small cohorts, lack of validation datasets, and technical variability (eg, scanner differences, patient iron load effects) are cited as reasons that the existing data are insufficient to support routine clinical adoption for many of these newer tests.

The document excerpts that support the investigational listings do not themselves present explicit 'not medically necessary' (NMN) scenarios beyond the overfrequency and duplicate testing constraints. Instead, investigational determinations are based on limited or inconsistent evidence in the literature, lack of multicenter validation, and guideline positions that advise cautious or limited use pending additional data. Where the policy designates a test investigational, corresponding CPT/ICD entries are listed as not covered for those indications.

The background summarizes the clinical context: hepatic fibrosis is progressive scarring from chronic liver injury of diverse etiologies. Liver biopsy remains the diagnostic gold standard, while noninvasive serum and imaging tests have been developed to estimate fibrosis and may reduce biopsy use in selected patients; however, evidence is limited and many studies are cross‑sectional with few long‑term outcome data.